ABSTRACT
INTRODUCTION
Despite the logical expectation that people with asthma would avoid exposure to cigarette smoke, studies suggest that the prevalence of active smoking among individuals with asthma is approximately the same as in the population at large. Thus, during 2005 the median adult smoking prevalence among all 50 States and the District of Columbia was 20.6% (1). Other studies, in the United States and abroad, have reported a smoking prevalence in asthmatics of 25-35% (2) (3) (4) (5) (6) (7) (8) . A recent survey of asthmatics presenting to Emergency Departments for treatment of asthma exacerbations found that 35% were smokers (9) . Moreover, even nonsmoking asthmatics may have significant exposure to passive smoke. In recent studies from Northern Italy, Canada, and the United States, 42-58% of asthmatics reported living with an active smoker or being exposed to cigarette smoke on a daily basis (10) (11) (12) , and 17.5% of Southern California school children in the Children's Health Study reported regular exposure to second hand smoke (13) .
If biological markers of environmental tobacco smoke exposure (e.g., serum cotinine) are used, up to 90% of asthmatics have evidence of exposure (14) .
Multiple outcomes are known to be worsened when asthmatics are exposed to cigarette smoke. For example, acute exposure to cigarette smoke triggers bronchoconstriction and symptoms in people with asthma (2, 15) . In addition, asthmatics who smoke regularly have more severe respiratory symptoms, worse quality of life, more emergency department visits and hospitalizations (8, 16) , and an accelerated loss of lung function, compared to asthmatics who do not smoke (17) .
Until recently there has been little information regarding the effect of cigarette smoking on the response to asthma therapy because most studies of asthma therapy have excluded subjects who smoke. Two recent studies of short-term administration of inhaled and oral corticosteroids have suggested that active smoking interferes with the response to corticosteroids (18, 19) . A third, larger, study suggested that smokers might benefit from higher doses of inhaled corticosteroid; however, the authors of that study cautioned that interpretation of their results is limited by small sample size and by a negative interaction test for a different effect of smoking in the low-vs high-dose inhaled corticosteroid group (20) . To our knowledge, no study has tested other, non-corticosteroid asthma therapies in subjects who smoke, especially in the same cohort.
Leukotrienes have been implicated in the pathophysiology of asthma, and leukotriene modifying drugs have been reported to be efficacious in the treatment of asthma (21) (22) (23) . In addition, studies have shown a dose-related increase in urinary LTE 4 excretion in response to cigarettes in habitual smokers (24) , an increase in 15-lipoxygenase activity in the airways of healthy smokers (25) , and a smoking-induced increase in urinary LTE 4 in asthmatics, but not in subjects with COPD or normals (26) . These studies provide the rationale for studying montelukast in athmatics who smoke.
If asthmatics who smoke do not respond to inhaled corticosteroids (or if they have a significantly blunted response), then the therapeutic ratio shifts significantly. In addition, the fiscal implications are enormous. If we assume that approximately 30% of the 17 million Americans with asthma smoke (2) (3) (4) (5) (6) (7) (8) (9) , and that approximately 60% have persistent asthma (27) , requiring 1 canister of inhaled corticosteroid per month at approximately $60/canister, then the cost of administering inhaled corticosteroids to this population would be $2.2 billion per year. We therefore performed this randomized, crossover trial, to examine whether the response to a relatively long (8 weeks) course of treatment with an inhaled corticosteroid or with a leukotriene receptor antagonist was blunted in asthmatics who smoke. This study, "Smoking Modulates Outcomes of Glucocorticoid Therapy" (SMOG), was sponsored by the National Institutes of Health and conducted by the National Heart, Lung and Blood Institute's Asthma Clinical Research Network.
METHODS

Subjects
This study was conducted between January, 2002 and February, 2004 at the 6 clinical sites that comprise the NHLBI's Asthma Clinical Research Network. Steroid naïve male and female subjects between the ages of 18 and 50 with a history of asthma (28) were recruited. All were required to have pre-bronchodilator FEV 1 70-90% of predicted and heightened airway reactivity as indicated by ≥12% reversibility after albuterol inhalation or by PC 20 methacholine <8mg/ml. Non-smokers were required to have a total lifetime smoking history of <2 pack-years, and no smoking for at least 1 year.
Subjects were enrolled as smokers if they were currently smoking 10-40 cigarettes/day, had a 2-15 pack-year smoking history, and a D L CO ≥ 80% of predicted. To avoid inclusion of subjects with COPD, exclusion criteria included age >50, smoking history >15 pack-years, active smoking of >40 cigarettes/day, and D L CO <80% of predicted.
Study Design
The study design was approved by an NHLBI Protocol Review Committee and Data Safety Monitoring Board, and by the Institutional Review Boards at each of the six ACRN clinical centers and the Data Coordinating Center. This was a randomized, double-blind, double-dummy, crossover trial of treatment with an inhaled corticosteroid (beclomethasone HFA, QVAR™, 160 mcg, twice daily) or an oral leukotriene receptor antagonist (montelukast, Singulair™, 10 mg, once daily) in subjects with mild-to-moderate asthma who were or were not current smokers. After a 2-week run-in period, to establish eligibility and adherence to study protocol and forms, subjects entered an 8-week singleblind placebo treatment period. Asthmatics who smoked and those who did not were then randomly assigned in parallel to receive either inhaled beclomethasone HFA or oral montelukast for eight weeks. At randomization, smoking and non-smoking subjects were matched according to gender, age, and FEV 1 % predicted, to ensure equal representation in the two groups. After the first 8-week treatment period subjects entered a 6-week placebo wash-out period, followed by a second 8-week period with the alternate treatment. Spirometry, methacholine reactivity, and asthma-specific quality of life were measured, and sputum induction was performed at the beginning and end of each treatment period. Urinary cotinine levels were measured at the beginning of each treatment period to validate smoking history.
Study Procedures and Measurements
At the time of first contact, all subjects who smoked were counseled and encouraged to attempt smoking cessation. Those who declined were enrolled in the study. Counseling and written referral to smoking cessation programs were provided again at the end of the study.
Written informed consent was obtained from all subjects, using forms that contained standard elements approved by the NHLBI, and that were approved by the individual Institutional Review
Boards at each institution. Routine history and physical examination and demographic information were recorded at the beginning of the run-in period. Spirometry and diffusing capacity were measured using standard techniques (29, 30) . To test reversibility, FEV 1 was measured before and 15 minutes after inhalation of up to 540 mcg of albuterol by a standardized procedure. Bronchial hyperresponsiveness was assessed by measuring the PC 20 methacholine (31). Asthma-specific quality of life was assessed with a well-validated instrument (32) . At the first visit subjects were provided with an electronic peak-flow meter (AM1™, Jaeger, Hoechberg, Germany) and a diary, and instructed in their twice-daily use. In addition, they received single-blind placebo medications. Pill bottles were fitted with an eDEM monitor™ (Aardex, Limited; Zug, Switzerland), and MDIs were fitted with a Doser™ device (MediTrack Products; Hudson, MA) to record opening of the pill container and actuation of the MDI, respectively. Sputum induction was performed as described previously (33) .
Personnel from all sites were trained and certified to perform sputum induction and to prepare slides for analysis, and quality control was maintained throughout the study by periodic over reading and grading of slides. All numerical counts for analysis were performed at a single site (UCSF). Cotinine was measured by a reference lab (National Medical Services, Willow Grove, PA).
Statistical Analysis
Descriptive statistics for continuous variables at baseline included means and standard deviations (or medians and quartiles for skewed distributions). The principal outcome was the change in prebronchodilator FEV 1 over the 8-week inhaled corticosteroid treatment period, comparing the change in FEV 1 in the group of smokers with that observed in the non-smokers. Secondary outcomes included AM-and PM-PEF, PC 20 methacholine, daily symptom scores, and quality of life measures.
To determine if differences between the smoking and non-smoking groups reflected differences in the character of inflammation, we examined induced sputum for total and differential cell counts, and for concentrations of eosinophil cationic protein and tryptase, as markers of airway inflammation, eosinophil activation, and mast cell activation, respectively. A mixed-effects linear model was applied that included a slope-intercept fit for the set of repeated measurements within each treatment period (Weeks 10-18 or 24-32), while accounting for (1) period and sequence effects from the crossover design and (2) correlations among the repeated measurements within a subject and within subject members of a matched pair (34) . Contrasts were then constructed to estimate the mean change between the end and beginning of the treatment periods.
The sample size calculation was performed using estimates for the standard deviation for improvement of FEV 1 after inhaled corticosteroid from prior ACRN studies (35, 36) . We calculated that 42 smokers and 42 non-smokers would provide 90% statistical power for detecting a 10% improvement in FEV 1 in non-smokers vs a 5% improvement in FEV 1 in smokers when inhaled corticosteroid was administered (primary outcome), and 73% power for detecting an 8% improvement in FEV 1 in non-smokers vs. a 4% improvement in FEV 1 in smokers when a leukotriene receptor antagonist was administered (secondary outcome). Our actual enrollment in this study was 83, providing 89% power for the inhaled corticosteroid comparison and 73% power for the leukotriene receptor antagonist, under the above assumptions.
Randomization and Blinding
Subject randomization was performed on-line via an Internet connection to the computer system at the Data Coordinating Center. When a subject was deemed eligible for study entry, a clinical center staff member entered and verified the pertinent data and received a drug packet number to give the subject. The study was triple-blinded in that subjects, clinical center personnel, and data analysts were all blinded to treatment identity. Treatment medication for each subject was packaged together, labeled with a unique number, and distributed to the clinical centers. The contents of the drug packages were known only to administrative personnel at the data coordinating center.
Role of the Funding Source
This study was funded by the National Heart, Lung & Blood Institute. The study was conceived, designed, implemented, conducted, analyzed, and interpreted by the investigators of the Asthma Clinical Research Network. The funding organization was not involved in the conduct of the study or in the collection, analysis, or interpretation of the data, nor did it have editorial authority or rights to decisions about publication. 3M, Inc. provided beclomethasone HFA inhalers and matching placebos, but had no input into the design, conduct, or interpretation of this study. Montelukast and matching placebo were purchased/prepared by the ACRN.
RESULTS
Participant Flow
One-hundred eighty-two subjects were screened for this study, and 141 entered the run-in at visit 1 (Figure 1 ). After 20 non-smokers and 38 smokers were excluded (Figure 1 ), 44 non-smokers and 39 smokers were randomized. Each matched pair was randomly assigned to treatment with either beclomethasone in the first treatment period followed by montelukast in the second, or the opposite sequence.
Subject Characteristics
Non-smokers and smokers were well matched at baseline (Table 1) . They did not differ significantly in any major demographic or physiologic characteristics. Subjects were, on average, 29 years old, and had asthma for ≥10 years. The average baseline FEV 1 was 78-80% of predicted, with a mean increase after albuterol of 16-18%. Median baseline PC 20 methacholine was 1.00-1.25 mg/ml, and baseline DLCO was normal in both groups. The smokers averaged 7 pack-years, had urinary cotinine levels of 975 (IQR 575, 1000), and despite similar baseline spirometry, reversibility and PC 20 methacholine measurements in the laboratory, had significantly lower daily AM peak flow, AM and PM symptom scores, worse asthma quality of life, and fewer lymphocytes in sputum compared with non-smokers.
Treatment Endpoints
In the asthmatic subjects who did not smoke, 8 weeks of treatment with inhaled beclomethasone was associated with significant increases in FEV 1 (170ml), FEV 1 % predicted (5%), PEF derived from spirometry (28 L/m), daily AM and PM PEF (12L/m, 7L/m), and PC 20 methacholine (0.63), and with a significant reduction in sputum eosinophils (-2.6%) ( Table 2 and Figures 2A-D) . In contrast, in the subjects who smoked, the same treatment had no significant effect on any of these variables except for daily AM PEF and sputum eosinophils (Table 2 and Figures 2A-D) . In general, the changes in the physiologic outcomes in the smokers were in the same direction as in the non-smokers, but were of smaller magnitude. The between-group differences were not statistically significant, although the greater improvement in FEV 1 in non-smokers trended toward significance (p=0.09).
In smokers, but not non-smokers, treatment with oral montelukast was associated with a significant increase in daily AM PEF (13L/m) (Table 2, Figure 2B ). When expressed as percent change from baseline, AM PEF increased 4.3% and 0.9% in smokers and non-smokers respectively, and the difference between groups was significant (p=0.02). Montelukast also decreased daily PEF variability in subjects who smoked (p=0.003), but improved Asthma Quality of Life in subjects who did not smoke. Neither smokers nor non-smokers had significant increases in their FEV 1 after 8 weeks of oral montelukast.
Analysis of the Doser™ Devices, eDEM™ Monitors, and diary cards demonstrated that adherence to inhaled and oral medication regimens was 77-92%, was not significantly different between smokers and non-smokers (p=0.13), and that concordance among the 3 methods of assessing adherence was good.
DISCUSSION
We compared the effects of monotherapy with an inhaled corticosteroid or a leukotriene receptor antagonist in two groups of subjects with mild asthma -one group who actively smoked cigarettes (total smoking history ~7 pack years) and another group who did not. We found that smokers differed from non-smokers in their responses to beclomethasone and montelukast. Treatment with inhaled beclomethasone was associated with a significant improvement in virtually every physiologic outcome in non-smokers, whereas the only significant change in smokers was in AM PEF. Treatment with montelukast resulted in only small changes in physiologic outcomes in non-smokers, whereas the change in AM peak flow was large in smokers compared to non-smokers. We conclude that cigarette smoking alters the response to inhaled corticosteroids and leukotriene receptor antagonists in asthmatic subjects.
Consistent with many other studies, we found that treatment with inhaled beclomethasone resulted in significant improvements from baseline in many outcomes of asthma control and airway function in non-smoking asthmatic subjects. In contrast, we found that the only significant improvements from baseline in smokers were in AM PEF, sputum eosinophils, and sputum ECP. Although these differences in treatment response between the non-smokers and smokers did not reach statistical significance, the consistency of the differences across outcomes and the consistency with prior data (18) (19) (20) provide convincing evidence that asthmatic subjects who smoke have an attenuated response to inhaled corticosteroids. There are a number of potential mechanisms by which habitual cigarette smoking may induce insensitivity to corticosteroids. Experimental data suggest downregulation of histone deacetylase (37) and/or enhanced neutrophil-mediated inflammation (38) in smokers. Increased levels of tumor necrosis factor-alpha, (39, 40) or changes in the ratio of the glucocorticoid receptor isoform GR-α to GR-β (41-44) have also been suggested as explanations for steroid insensitivity. In fact, Livingston et al. have reported that the GR-α to GR-β ratio is reduced in peripheral blood mononuclear cells of cigarette smokers (45) . Our study and others (24) suggest that production of cysteinyl leukotrienes may be important.
The increase in FEV 1 after inhaled beclomethasone seen in non-smokers in this study averaged 5%
and was less than the 10-20% reported in many published studies, including our own (35, 36, 46) .
Possible explanations for this result are that the subjects had mild asthma (although they had documented albuterol reversibility of approximately 15%), or that they received too little inhaled corticosteroid. The subjects did, in fact, have baseline characteristics very similar to the subjects with mild persistent asthma studied in IMPACT (47), in which the response to treatment with inhaled corticosteroid for 1 year was nearly identical (4%) to that obtained in the current study (5%). The inhaled corticosteroid chosen for this study, hydrofluoroalkane (HFA)-beclomethasone dipropionate (BDP) ("QVAR™"), is a chlorofluorocarbon (CFC)-free preparation with corticosteroid in solution rather than suspension, a formulation thought to produce an extrafine aerosol which deposits more distally in the lung than CFC-BDP. Because of increased lung deposition of HFA-BDP relative to CFC-BDP, asthmatic patients require half the daily dose to achieve the same degree of asthma control (48) . Thus, the dose of 160 mcg twice daily used here can be considered equivalent to a dose of 320 mcg twice daily of CFC-BDP. This is not a low dose, and we think it unlikely that the smaller-than-expected response in non-smokers is due to under-dosing, especially since adherence, inferred from 3 separate measures, was close to 90%. An alternative explanation is that we recruited, by chance, a group of non-smoking asthmatics whose response to HFA-BDP was modest. Asthmatic subjects show considerable heterogeneity in their responsiveness to inhaled corticosteroids as demonstrated in a prior study in which approximately one third of inhaled corticosteroid naïve subjects had a poor response to this treatment (35) .
Montelukast produced a statistically significant increase in AM PEF and a decrease in PEF variability in smokers, and these changes were significantly greater than its effects seen in non-smokers.
These findings may be explained by enhanced leukotriene synthesis or sensitivity in smokers.
Urinary excretion of LTE 4 is closely correlated with the number of cigarettes smoked daily, and urinary LTE 4 levels increase significantly in non-smokers who smoke six cigarettes in 12 hours (24). Gaki et al. have reported that smoking increases urinary LTE 4 in patients with asthma, but not in normals or patients with COPD (26) . Habitual smokers such as those enrolled in our study may therefore have chronically elevated leukotriene levels that may render them responsive to treatment with cysteinyl leukotriene receptor antagonists. Although the smoking asthmatics had a significant response to montelukast in terms of AM peak flow and sputum ECP, other outcomes were not similarly improved.
For example, in smokers, the effects of montelukast on FEV 1 , PC 20 methacholine, asthma symptoms, and asthma quality of life were not significantly greater than in non-smokers. Nevertheless, our data for improvement in AM peak flow warrant follow-up in larger studies, including studies of the effects of leukotriene pathway modifiers on asthma exacerbation rates in smokers.
Relatively few studies have focused on the effects of cigarette smoking on outcomes of asthma control and airway inflammation in asthmatic subjects. In this regard we would emphasize some important observations made during the initial characterization visits of the study. First, despite smoking at least 10 cigarettes per day for an average of 7 years, smokers with asthma demonstrated, at baseline, albuterol reversibility and methacholine reactivity that were very nearly identical to nonsmokers. Second, despite similar FEV 1 , FEV 1 % predicted, reversibility, and response to methacholine, the asthmatics who smoked had significantly more symptoms (across all symptom domains), worse asthma-specific quality of life, and lower PEF measured daily at home than did the non-smokers. These findings are consistent with previous studies that have described worse clinical status in asthmatics who smoke (8, 16, 17) . Although several studies have reported that smokers with chronic airflow obstruction have fewer symptoms with induced bronchoconstriction than asthmatics with similar obstruction (49, 50) , perhaps due to depletion of neurotransmitters from sensory nerves (50) , the ability to perceive induced bronchoconstriction could not be predicted by smoking history (49) . Taken together, these data demonstrate that laboratory-based testing does not capture the impact of cigarette smoking on disease severity in asthma that is captured by daily symptom diaries and quality of life measures. Third, the baseline sputum cell profiles did not differ based on smoking status: We found no differences in the percentages of eosinophils or neutrophils in induced sputum obtained at baseline. We expected to find increased sputum neutrophils in smokers because smoking has been associated with neutrophilic inflammation in the airways (38, 51) that improves with smoking cessation (51, 52) , and inhalation of cigarette smoke has been shown to induce chemotactic attraction of neutrophils, probably through induction of release of interleukin-8 (53, 38) . Our data may be explained by the relatively young age of the asthmatic subjects in our study and their relatively modest smoking history; most studies demonstrating that cigarette smoke causes inflammation and remodeling have enrolled older subjects with high pack-years of smoking.
These results suggest that sputum neutrophilia may be a marker of heavy smoking and may not be causally related to the development of steroid insensitivity in asthmatics who smoke cigarettes habitually.
Taken together, our data and those of others suggest that corticosteroid resistance occurs in asthmatics who smoke and should be considered when prescribing treatments for this asthmatic subgroup. For example, Tomlinson has suggested that these patients may benefit from increased inhaled corticosteroid dose (20) . In addition, for some asthma control outcomes, we found that the lung function response to montelukast was better in asthmatics who smoke than in non-smokers.
These data are not sufficient to warrant a change in treatment algorithms, but indicate the need for larger studies to further explore the utility of inhibiting leukotrienes in asthmatics who smoke cigarettes. Meanwhile, our data suggest the need for a specialized approach to asthmatic patients who smoke. Clearly, ongoing counsel and assistance with smoking cessation is essential. In addition, because of differences in treatment response, further trials are warranted to establish the optimal management strategies for asthmatic subjects who are unwilling or unable to stop smoking. 
